The UK and US have concluded a significant bilateral deal that will keep no tariffs on British drug shipments going into the American market.
The Terms of the Pact
As part of the deal, the UK has committed to raise funding on medicines through the NHS. This move guarantees that import taxes on these crucial goods will remain at zero for a duration of three years.
This agreement follows earlier statements to significantly raise import taxes on patented drug imports, with figures discussed as high as one hundred percent.
"This deal between the Britain reinforces the international landscape for cutting-edge drugs and introduces long-overdue fairness to transatlantic pharmaceutical trade," a statement noted.
Economic Impact
Drugs represent one of the UK's most significant exports to the America, which is by far the largest market for large UK drugmakers.
Export figures indicate that in the one-year period prior to September, the UK sold drugs worth billions to the US. This amount accounted for 17.4% of total UK exports in that period.
"This deal protects employment, stimulates funding and facilitates the UK to establish itself as a global hub for life sciences," a government official stated.
Key British Pledges
The deal entails several specific commitments from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a aim to double total public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount drug companies must return to the NHS to control costs will be limited at 15%. Last year, repayments exceeded 20%.
Recent Tensions
The pact takes place against a ongoing dispute between the sector and the ministers over medicine costs and approval rates.
This friction were intensified by assertions that US patients were charged several times more for the same drugs than patients in the Britain and the EU.
Recently, several large drug company projects in the UK have been delayed or cancelled, while substantial investments have been directed toward American operations.
A senior figure publicly accepted that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a share of its overall budget over the previous ten-year period.
